Dermatitis Drugs Market

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global dermatitis drugs market was valued at US$ 5.8 billion in 2021 and is expected to register a revenue CAGR of 14.60% to reach US$ 19.77 billion by 2030.

Market Fundamentals

The global dermatitis drugs market is expected to register high revenue growth during the forecast period, due to the consistent growth in the disease prevalence globally. There is a notable growth in the prevalence of atopic dermatitis, thereby growing the demand for atopic dermatitis treatments. Furthermore, the proliferation of patient communities and support groups and improving awareness are also supporting the growth in dermatitis drugs demand. Based on these grounds, the global dermatitis drugs market forecast is estimated to be promising. 

The term dermatitis describes a typical skin irritation, commonly caused by fungal and viral infections. Symptoms of dermatitis include dry, itchy skin or a rash. The skin could also blister, leak, crust, or flake. The immune system can sometimes react strongly in dermatitis by responding to allergens that seem insignificant in atopic dermatitis. Atopic dermatitis and contact dermatitis are the two types studied in this report on the global dermatitis drugs market. The prevalence of atopic dermatitis has increased in the middle-aged patient group. It is more prevalent in males 75 of age and older. The severity and activity of atopic dermatitis in older individuals is greater than in children of 0-17 and adults ages 18-74 years. Immunosuppressant drugs such as cyclosporine, azathioprine, methotrexate, and mycophenolate mofetil are frequently prescribed drugs for atopic dermatitis which is expected to support the global revenue growth of the dermatitis drugs market. 

[875904]

Market Dynamics

The growing prevalence of dermatitis is the primary factor driving the revenue growth of the global dermatitis drugs market. Furthermore, because of increased adoption of Interleukin -4 inhibitors like dipilumab, which is marketed under the brand names dupixent by Sanofi and Regeneron Pharmaceuticals, and Eucrisa by Ancor Pharmaceuticals, an increase in research and development for producing novel drugs are also driving the revenue growth of the global dermatitis drugs market. However, stringent government regulations and constricted pipelines are major restraints to the market revenue growth.

Market Ecosystem

The global dermatitis drugs market is analyzed from four perspectives: drug class, disease type, distribution channel, and Region. 

Global Dermatitis Drugs Market by Drug Class

[298450]

Based on the drug classes, the global dermatitis drugs market is segmented into biologics, PDE4 inhibitors, corticosteroids, and calcineurin inhibitors. 

Corticosteroids, the first line of treatment, accounts for the highest revenue share in the dermatitis drugs market. The actions of hormones can be imitated with corticosteroids. In addition to decreasing inflammation, they can reduce immune system hyperactivity, which can aid in the process known as vasoconstriction, which causes the blood vessels to tighten. 

Medications derived from animal or human proteins are known as biologics. Biologics are made to particularly target the biological processes that result in skin and other organ inflammation. The rapid influx of biologics is expected to be seen during the forecast period as biologics offer targeted therapies, which do not go through the whole system hence offering few side effects than other treatments. 

Global Dermatitis Drugs Market by Disease Type

Based on the disease types, the global dermatitis drugs market is segmented into atopic dermatitis and contact dermatitis. 

Between the two, the atopic dermatitis segment shall continue to dominate the dermatitis drugs demand during the forecast period. The key reason behind the dominant status of atopic dermatitis is the perpetual increase in incidence, owing to the improving awareness and diagnosis methods. As reported in the Acta Derm Venereologica Journal, the 2020 prevalence of atopic dermatitis in adults was 17.1% in Europe, which was further magnified in children. Furthermore, improvement in the pipeline candidates for atopic dermatitis treatment is also observed. 

On the other hand, there was a spike in the incidence of contact dermatitis during the COVID-19 pandemic. The incidence of hand eczema rose due to frequent hand washing. This created high demand for specialized creams and ointments for contact dermatitis treatment. 

Global Dermatitis Drugs Market by Distribution Channel

Based on the distribution channel, the dermatitis drugs market is segmented into hospitals, aesthetic clinics, and pharmacies. 

Trends indicate that the pharmacies segment shall continue to lead the global dermatitis drugs market. The revenue growth of this segment is attributed to the widespread availability of topical over-the-counter drugs for the treatment of both atopic dermatitis and contact dermatitis. The position of pharmacies is further strengthened in the sAsia Pacific market, as the demand for generic medications is high in the region. Furthermore, the demand for biologics is also gradually rising in the Asia Pacific market, with growing availability in pharmacy sales channels. 

Global Dermatitis Drugs Market by Disease Type 

Based on the type of disease, the global dermatitis drugs market is segmented into atopic dermatitis, and contact dermatitis. 

The dermatitis drugs market is currently being dominated by atopic dermatitis, mainly attributed to the larger prevalence rate. The prevalence of atopic dermatitis is rising due to the development of efficient medications, the prevalence of the condition, and better disease diagnostics. In addition, according to JAAD International, up to 2.4% of people worldwide are affected with atopic dermatitis (AD). Therefore, a high patient pool and higher treatment requirements for atopic dermatitis contribute to the dominant revenue share of the atopic dermatitis segment in the dermatitis drugs market. 

Global Dermatitis Drugs Market by Region 

Based on the region, the global dermatitis drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

In terms of revenue share, North America dominates the market. The high revenue growth is attributed to the high prevalence of dermatitis in the region, high awareness, and the presence of several market players. 

The Europe dermatitis drugs market is growing due to increased healthcare expenses, the availability of robust reimbursement policies, and high research and development on the disease. 

The Asia Pacific dermatitis drugs market is expected to register high revenue growth during the forecast period due to increased healthcare expenditure, growing disposable incomes,  improving awareness among the population, and consistent growth in diagnosis rates.

Competitive Landscape

The prominent players operating in the global dermatitis drugs market are:

• Bayer AG
• LEO Pharma A/S
• Pfizer, Inc. 
• Sanofi SA
• Mylan N.V. 
• Allergan, Inc.
• Anacor Pharmaceuticals, Inc. 
• Regeneron Pharmaceuticals, Inc. 
• Bausch Health Companies, Inc. 
• Teva Pharmaceuticals Industries Ltd. 

Strategic Developments

• In September 2021, The Opzelura (ruxolitinib) ointment was approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate atopic dermatitis in patients 12 years of age and older.

Frequently Asked Questions About This Report